A Trial of Androgen Deprivation, Docetaxel, and Enzalutamide for Metastatic Prostate Cancer
Status:
Active, not recruiting
Trial end date:
2028-03-01
Target enrollment:
Participant gender:
Summary
This is a study with the combination of androgen deprivation therapy (ADT) and docetaxel with
the addition of enzalutamide in the treatment of subjects with metastatic prostate cancer.
The purpose of this study is to assess if ADT + docetaxel + enzalutamide is well tolerated
and demonstrates improved efficacy compared to ADT + docetaxel.